Key result
Apabetalone suppresses doxorubicin-induced endothelial senescence and rescues vascular and cardiomyocyte dysfunction.
Why the study?
The contribution of endothelial cells and BET epigenetic remodeling to doxorubicin-induced cardiovascular toxicity remains elusive.
Does the selective BET inhibitor apabetalone prevent doxorubicin-induced endothelial senescence, vascular dysfunction, and paracrine cardiotoxicity in human endothelial cells, ex vivo arterial models, and cardiac spheroids?
Does the selective BET inhibitor apabetalone prevent doxorubicin-induced endothelial senescence, vascular dysfunction, and paracrine cardiotoxicity in human endothelial cells, ex vivo arterial models, and cardiac spheroids?
Preclinical findings demonstrate that BET inhibition with apabetalone mitigates doxorubicin-induced endothelial senescence and paracrine cardiotoxicity, suggesting a potential therapeutic strategy for preventing anthracycline-related cardiovascular dysfunction.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for BET inhibition to mitigate doxorubicin cardiotoxicity; requires prospective trials before clinical adoption.
Background Anthracyclines such as doxorubicin (DOXO) are highly effective anticancer agents but induce cardiovascular toxicity. While DOXO-induced cardiomyocyte injury has been extensively studied, the contribution of non-cardiomyocytes populations, particularly endothelial cells (ECs), remains elusive1. Bromodomain and extra-terminal (BET) proteins, especially BRD4, act as chromatin readers translating histone acetylation into transcriptional activation, and are emerging a pivotal pleayers in cardiovascular disease. Purpose To investigatethe role BET epigenetic remodeling in DOXO-induced endothelial dysfunction. Methods Human aortic endothelial cells (ECs) were exposed to DOXO (50–500 nM) in the presence or in the absence of the selective BET inhibitor Apabetalone (RVX-208). Senescence markers and chromatin remodeling were assessed using RNA-seq, proteomics, ATAC-seq as well as BRD4 ChIP-seq[FP1] . Vascular function was evaluated ex vivo in mouse aortic rings and human internal mammary arteries. Paracrine effects of ECs were examined using endothelial-conditioned media applied to naïve ECs, cardiomyocytes, and iPSC-derived 3D cardiac spheroids. Results DOXO induced dose-dependent ECs senescence, shown by increased p53, p21, γH2AX and SA-β-gal positivity. RNA-seq revealed profound transcriptional reprogramming involving cell adhesion pathways, epigenetic regulators, and senescence associated secreted phenotype (SASP) factors. BET inhibition with RVX-208 suppressed p53/p21 induction, normalized SASP, restored endothelial morphology, and reduced SA-β-gal positivity (Fig. 1). Among BET proteins, BRD4 (but not BRD2/3) was the main driver of pro-senescent programs. ATAC- and ChIP-seq in DOXO-treated ECs demonstrated enhanced BRD4 occupancy at gene loci controlling senescence (Fig. 2), whereas RVX-208restored rejuvenation-associated genes (c-MYC, NANOG, KLF4). Conditioned media from DOXO-treated ECs induceda senescent phenotype in naive ECs and impaired migration and tube formation. Secretome proteomics revealed enrichment of SASP-associated mediators, indicating establishment of a pro-inflammatory paracrine milieu. This endothelial stress signal propagated beyond the vasculature, triggering stress responses in cardiomyocytes and destabilizing multicellular 3D cardiac spheroids. BET inhibition normalized maladaptive secretome changes and prevented ECs-driven cardiomyocyte dysfunction. Of note, ex vivo treatment with RVX-208 restored DOXO-impaired endothelial relaxation and sprouting in mouse arteries. Of clinical relevance, human internal mammary arteries exposed to DOXO exhibited BET upregulation and endothelial dysfunction, which was rescued by RVX-208. Conclusions BET-driven transcriptional programs are heavily implicated in DOXO-induced ECs damage. BET inhibitors may represent promising drugs to mitigate cardiovascular dysfunction in cardio-oncology patients.
No takes yet. Share an insight, caveat, or question.
Mohammed et al. (2026) studied Doxorubicin-induced endothelial dysfunction and cardiotoxicity. Apabetalone (RVX-208) vs. Doxorubicin (50-500 nM) without Apabetalone was evaluated on Endothelial cell senescence, chromatin remodeling, vascular function, and paracrine cardiotoxicity. Selective BET inhibition with Apabetalone (RVX-208) suppressed doxorubicin-induced endothelial senescence, normalized secretome changes, and rescued ex vivo vascular and cardiomyocyte dysfunction.
Synapse has enriched 10 related papers. Consider them for comparative context: